FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 ( ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 4.01 million shares due to the exercise of options on November 26, 2025 [1] Summary by Relevant Categories - **Company Actions** - WuXi Biologics will issue 4.01 million shares as a result of option exercises [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 4.01 million shares due to the exercise of options on November 26, 2025 [1] Summary by Relevant Sections - Company Actions - WuXi Biologics will issue 4.01 million shares as a result of option exercises [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 6.05 million ordinary shares on November 25, 2025, as part of the stock option plan adopted prior to its initial public offering on January 5, 2016, which was revised on August 10, 2016 [1] Group 1 - The company is exercising options under its pre-IPO stock option plan [1] - A total of 6.05 million ordinary shares will be issued [1] - The announcement is part of the company's ongoing equity management strategy [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 6.05 million ordinary shares on November 25, 2025, as part of its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Group 1 - The company will issue 6.05 million ordinary shares [1]

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | | 2025年11月19日 | | 4,107,272,633 | | 0 | | 4,107,272,633 | | 1). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | | | 4,000 | 0.0001 % | HKD | 1.67 ...

Summary of WuXi Biologics Conference Call Company Overview - **Company**: WuXi Biologics (2269.HK) - **Event**: APAC Healthcare Corporate Day 2025 - **Date**: November 20, 2025 Key Industry Insights - **New Order Momentum**: Management indicated that new order momentum remains robust as the company heads into Q4 2025, with expectations for accelerated revenue and earnings growth in 2026 [2][3] - **R&D Projects**: A rebound in R&D projects was noted, driven by global funding recovery and increased PPQ scheduling. Bi-/multi-specific antibodies and ADCs are identified as key growth drivers, with respective project increases of +36.6% y/y to 168 projects and +34.7% y/y to 225 projects, together accounting for 71% of new projects as of 1H25 [3][2] Financial Performance and Projections - **Revenue Guidance**: Management plans to provide further clarity on revenue and project guidance at an industry conference in early 2026, with detailed updates expected during the full-year earnings release in March 2026 [2] - **Capex Plan**: The annual capital expenditure (capex) budget is projected to exceed RMB 5 billion through 2027, focusing on overseas expansion. Long-term capacity is targeted to reach 500kL, with 50% of this capacity located in China [4][7] Operational Efficiency - **Margin Management**: The margin dilution from the Singapore site is considered manageable due to favorable tax policies and operational efficiencies. Utilization rates at domestic sites have improved from 60% to 65% and are expected to continue rising [8][2] - **Project Updates**: A project at the Shijiazhuang site has received Breakthrough Therapy Designation (BTD) and is targeted for Biologics License Application (BLA) filing by year-end, which could significantly enhance utilization post-launch [8] Risks and Price Target - **Price Target**: The 12-month price target is set at HK$33.50, based on a forward P/E of 26x, indicating a potential upside of 4.9% from the current price of HK$31.92 [10] - **Risks**: Key risks include potential legislative impacts on US revenue, cooling of global biotech funding, and increasing competition from global players [9][10] Conclusion WuXi Biologics is positioned for growth with strong order momentum and strategic expansion plans. The focus on R&D and operational efficiency, alongside a robust capex plan, supports the company's outlook for 2026. However, investors should remain cautious of external risks that could impact performance.

Core Points - WuXi Biologics (02269) announced the issuance of a total of 1.502 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - **Company Announcement** - WuXi Biologics issued 1.502 million ordinary shares [1] - The issuance is related to the exercise of options from the pre-IPO share option plan [1] - The plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 1.502 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company has issued 1.502 million ordinary shares as a result of exercising options under its share option plan [1]